Micheal Binks

Dr. Micheal Binks joined Capricor in 2025 and currently serves as our Chief Medical Officer. Dr. Binks, a distinguished leader in the industry, is a board-certified rheumatologist (UK) and internationally recognized expert in immunology and rare disease. Prior to Capricor, Dr. Binks held senior leadership roles at both Pfizer and GlaxoSmithKline, where he was instrumental in advancing multiple first-in-class therapies, including Benlysta, Hympavzi, Paxlovid and Beqvez, as well as multiple gene therapy, small molecule and biologics programs currently in early and late-stage development. Most recently, Dr. Binks served as Vice President and Head of Rare Disease Clinical and Translational Research, Worldwide Research Development and Medical at Pfizer, based in Cambridge, MA, where he led global efforts overseeing more than a dozen clinical studies, including several in Duchenne muscular dystrophy (DMD). His experience spans a broad range of therapeutic areas, including immunology, neurology, cardiology, nephrology and hematology. In addition to his pharmaceutical leadership roles, Dr. Binks is the founder of PathfindRx LLC, a translational medicine consultancy, and has held honorary academic and clinical appointments at institutions including Addenbrooke’s Hospital in Cambridge and University College London. He received his medical degree, postgraduate, and specialist training from University College London Medical School.